pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
466
stories
8d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
8d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
8d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
8d
Scynexis bags $214M BARDA contract for antifungal development
fiercebiotech
8d
Kids shouldn’t have to organize childhood around medicine
biopharma dive
8d
6 immunology targets to sustain a mammoth I&I market
biospace
12d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
12d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
12d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
12d
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
biospace
12d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
12d
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
13d
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
13d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
13d
Enveda reaps $311M series E to feed ambition to become a ‘household name’
fiercebiotech
14d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
14d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
14d
2026 IPO blitz continues with 4 new biotech filings
biospace
14d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
14d
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
14d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
15d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
15d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
15d
Behind the outcomes: How whole-patient support is reshaping oncology care
biopharma dive
15d
Are healthcare systems really ready for GLP-1s?
biopharma dive
15d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
18d
FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
endpoints
18d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
18d
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
19d
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
← prev
page 2 of 16
next →
